Please ensure Javascript is enabled for purposes of website accessibility

Theravance Inc. Stock Was Up 14% in December -- Here's Why

By Brian Feroldi - Jan 10, 2016 at 12:07PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Low interest in the company's tender puts investors in a good mood.

What: Shares of Theravance Inc (NASDAQ: THRX), a healthcare royalty company, put up another greatly monthly performance as the company's stock moved more than 14% higher during the month of December, according to data from S&P Capital IQ.

THRX Chart

So what: The only news the company released during the month was the preliminary results of its previously announced tender offer that it authorized in October. At the time, Theravance thought its stock was deeply undervalued, and made the decision to stop paying a dividend and use the capital to repurchase its shares, choosing to do so via a modified Dutch action. The company had authorized itself to repurchase $75 million worth of its common stock from investors that were interested in selling at a price between $8.50 and $9.25. Shareholders who wanted to take part had to indicate how many shares they wanted to sell and the lowest price they were willing to accept. Theravance would then buy back up to $75 million shares at the lowest price offered.

The preliminary results showed that investors were not very interested in selling at that price, as only 2.5 million shares were tendered for a total value of about $24 million. That's less than a third of what the company had authorized, indicating that its investors felt its shares were still undervalued.

Now what: Theravance's stock has bounced back strongly since crashing in September after its partner GlaxoSmithKline (GSK 0.84%) announced that a phase 3 trial designed to evaluate Relvar/Breo Ellipta's ability to reduce the risk of cardiovascular death in COPD patients failed to demonstrate statistically significant results. Given that the majority of Theravance's revenue is directly tied to GlaxoSmithKline's ability to sell Relvar/Breo Ellipta, many traders saw the news and simply headed for the exits. If the trial had shown better clinical news, GlaxoSmithKiline would have had an easier time selling Relvar/Breo Ellipta, which would have benefited Theravance directly.

While the markets have been cheering Theravance's stock in recent months, I continue to believe it still has too much debt on its balance sheet. Until that changes, I'm content to stay far away from this stock.

Brian Feroldi has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

GSK Stock Quote
GSK
GSK
$36.03 (0.84%) $0.30

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/15/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.